Category

Archives

Blog of Signaling Pathways

Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

12 views | Sep 23 2020

Sara M Tolaney et al .showed that Ribociclib plus fulvestrant demonstrated safety in the treatment of patients with HR+, HER2- ABC. [Read the Full Post]

AGE-Induced Suppression of EZH2 Mediates Injury of Podocytes by Reducing H3K27me3

12 views | Sep 23 2020

Marita Liebisch et al. provided a novel pathway how AGEs contributed to podocyte injury and the formation of the so-called metabolic memory in DKD. [Read the Full Post]

Transient Receptor Potential Ankyrin 1 (TRPA1) is Up-Regulated in Response to Lipopolysaccharide via P38/ Mitogen-Activated Protein Kinase (MAPK) in Dental Pulp Cells and Promotes Mineralization

23 views | Sep 22 2020

Kento Tazawa et al. demonstrated that LPS stimulation induced TRPA1 via the NO-p38 MAPK signaling pathway and TRPA1 agonists promoted differentiation or mineralization of dental pulp cells. [Read the Full Post]

Nullifying epigenetic writer DOT1L attenuates neointimal hyperplasia

17 views | Sep 22 2020

Yitao Huang et al. presented a strong rationale for continued mechanistic and translational investigation into DOT1L targeting for treatment of (re)stenotic vascular conditions. [Read the Full Post]

Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis

17 views | Sep 21 2020

Rajesh K Kasam et al. provided important proof-of-concept that demonstrated barasertib as a possible intervention therapy for IPF. [Read the Full Post]

Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets

15 views | Sep 21 2020

Julia Krushkal et al. indicated potential epigenetic mechanisms affecting SCLC response to chemotherapy and suggested targets for combination therapies. [Read the Full Post]

Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells

13 views | Sep 19 2020

Zina Sarif et al. indicated a high relevance of Mcl-1 targeting also in melanoma therapy. [Read the Full Post]

FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

16 views | Sep 19 2020

Jinglin Zhang et al. highlighted the translational potential of FGFR2-c-Jun-YAP1 axis, which might serve as a prognostic biomarker and therapeutic target for GC. [Read the Full Post]

Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma

15 views | Sep 17 2020

Sean Hacking et al. supported the theoretical foundation for targeting PD-L1 and IDO-1 in CRC, which now needed verification in well-designed robust clinical trials. [Read the Full Post]

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

16 views | Sep 17 2020

Souvik Dey et al. found that the in vivo antitumor effects demonstrated with IDO1-based vaccines via targeting of the tumor microenvironment highlighted the utility of mouse models for further exploration and refinement of this novel vaccine-based approach to IDO1-directed cancer therapy and its potential to improve patient response rates to anti-PD1 therapy. [Read the Full Post]

Mst1 promotes mitochondrial dysfunction and apoptosis in oxidative stress-induced rheumatoid arthritis synoviocytes

16 views | Sep 16 2020

Yingjie Wang et al. suggested the Mst1-AMPK-Sirt1 axis was a potential target for RA therapy. [Read the Full Post]

SIRT1 Mediates Neuropathic Pain Induced by Sciatic Nerve Chronic Constrictive Injury in the VTA-NAc Pathway

20 views | Sep 16 2020

Yangyang Li et al. proposed that the discovery of the effect of SIRT1 on neuropathic pain in the VTA represented an important step forward in understanding the analgesic mechanisms of the VTA-NAc pathway. [Read the Full Post]

Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion

16 views | Sep 15 2020

Yifat Koren Carmi et al. showed the potential of combining flavonoids with standard therapy to restore drug sensitivity to OC cells and overcomed TME-mediated platinum drug resistance. [Read the Full Post]

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer

12 views | Sep 15 2020

Jennifer Ferris et al. suggested that this second-generation proteostasis-disrupting agent might have its most widespread activity in CRC, in combination with irinotecan-containing treatment regimens. [Read the Full Post]

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia

22 views | Sep 14 2020

Jun Long et al. demonstrated that HDAC8 upregulation was an important mechanism to resist TKIs and promote leukemia maintenance and suggested that combining HDAC8 inhibition with TKI treatment could be a promising strategy to treat FLT3-ITD+ AML and other tyrosine kinase mutation-harboring leukemias. [Read the Full Post]

Proliferation of Vascular Smooth Muscle Cells under ox-LDL Is Regulated by Alismatis rhizoma Decoction via InhibitingERK1/2 and miR-17∼92a Cluster Activation

25 views | Sep 14 2020

Julian Shen et al. provided the multitarget mechanisms for application of AD in the treatment of atherosclerosis. [Read the Full Post]

Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches

23 views | Sep 13 2020

Tomohiro Sato et al. indicated the existence of the additional hydrogen bond via water molecules restricting the attachment point in the pyrazole scaffold [Read the Full Post]

Quizartinib for the treatment of acute myeloid leukemia

21 views | Sep 13 2020

Alejandro Garcia-Horton et al. reviewed the mechanism of action, pharmacology, clinical efficacy, and safety of quizartinib, a FLT3 inhibitor, for the treatment of acute myeloid leukemia. [Read the Full Post]

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer

0 views | Sep 11 2020

Vanita Noronha et al. found that adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC. [Read the Full Post]

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

17 views | Sep 11 2020

Rebecca L Lloyd et al. provided a mechanistic understanding of combined PARP and ATR inhibition in ATM-deficient models, and supported the clinical development of AZD6738 in combination with olaparib. [Read the Full Post]